home / stock / agn:cc / agn:cc news

AGN:CC News and Press, Algernon Pharmaceuticals Inc. From 04/18/23

Stock Information
Company Name: Algernon Pharmaceuticals Inc.
Stock Symbol: AGN:CC
Market: CNQC
Menu
AGN:CC AGN:CC Quote AGN:CC Short AGN:CC News AGN:CC Articles AGN:CC Message Board
Get AGN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AGN:CC - Algernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASH

--News Direct-- Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work on chronic kidney disease. Moreau tells Proactive the patent, which is titled “Compositions ...
AGN:CC - Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has receive...

AGN:CC - Algernon NeuroScience reports successful second cohort dosing in DMT clinical study

--News Direct-- Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has completed dosing of the second cohort in the Phase 1 clinical study of DMT. Moreau tells Proactive the study is to id...

AGN:CC - Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

VANCOUVER, British Columbia, April 04, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its s...
AGN:CC - Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...

AGN:CC - CSE Bulletin: New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

Toronto, Ontario--(Newsfile Corp. - Le 27 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a Rights Offering to eligible shareholders of record at the close of market on March 29, 2023. A holder resident in an Eligible Jurisdiction will be offered one (1) transferable right for each...

AGN:CC - Algernon Pharmaceuticals Announces Launch of Rights Offering

VANCOUVER, British Columbia, March 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a right...
AGN:CC - Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary...

AGN:CC - CSE Bulletin: Stock Split - Algernon Pharmaceuticals Inc. (AGN)

Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive three (3) additional share...

AGN:CC - Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

VANCOUVER, British Columbia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that effective at the opening of mar...
Previous 10 Next 10